Cell Therapy
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
30
NCT06249438
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Phase: Phase 1
Role: Collaborator
Start: Mar 20, 2024
Completion: Mar 31, 2040
Loading map...